• In late June 2026, Teladoc Health, Inc. was removed from several Russell Growth benchmarks, including the Russell 2000, 2500, 3000, 3000E, and Small Cap Composite Growth indexes.
• This broad index exclusion can matter for Teladoc because it often prompts mechanical selling by index-linked funds, reshaping the company’s institutional ownership base.
• We’ll now examine how Teladoc’s removal from multiple Russell Growth indexes may influence its investment narrative and future risk profile.

This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

Teladoc Health Investment Narrative Recap

To own Teladoc today, you need to believe virtual care can steadily deepen its role in chronic disease and mental health management, even as the company remains unprofitable. The Russell Growth index removals may add some share price volatility and near term technical pressure, but they do not directly change the core fundamental catalyst around product adoption or the key risk that BetterHelp’s margin mix and competition could weigh on Teladoc’s path to earnings improvement.

The recent Walmart Better Care Services partnership stands out here. It extends Teladoc’s reach across both insured and cash pay users, which ties directly into the company’s effort to grow visit volumes and strengthen its integrated care offering. That same shift toward more visit based revenue, however, also intersects with concerns about reimbursement uncertainty and unit economics that could influence how this catalyst ultimately plays through Teladoc’s financials.

Yet, while index removal may feel technical, the real risk investors should be aware of is how persistent reimbursement and margin pressure could...

Teladoc Health's narrative projects $2.6 billion revenue and $173.1 million earnings by 2029. This assumes revenue remains fairly flat each year and a $344.2 million earnings increase from -$171.1 million today.

Uncover how Teladoc Health's forecasts yield a $7.40 fair value, a 12% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming Teladoc’s revenue might shrink about 1.1% a year and still not reach profitability by 2029, so the latest index exit could further test whether you side more with that cautious view or the more optimistic story around expanding partnerships and better cost control.

Explore 4 other fair value estimates on Teladoc Health - why the stock might be worth as much as 70% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Teladoc Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Teladoc Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teladoc Health's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.